Mustapha J A, Diaz-Sandoval Larry J
Department of Medicine, Metro Health Hospital, Michigan State University, College of Osteopathic Medicine, MI.
Department of Medicine, Metro Health Hospital, Michigan State University, College of Osteopathic Medicine, MI.
Tech Vasc Interv Radiol. 2014 Sep;17(3):183-96. doi: 10.1053/j.tvir.2014.08.007. Epub 2014 Aug 23.
Tibial arterial disease represents the final frontier in the battle against critical limb ischemia (CLI). Isolated infrapopliteal (IP) disease is mainly seen in the elderly (>80 years old), diabetic, and dialysis-dependent patients with CLI. With the development and evolution of catheter-based technology, endovascular therapy (mainly balloon angioplasty) has become the method of choice for revascularization in these patients. The most common challenges are the severely calcified lesion recalcitrant to dilation (as calcium is heterogeneously distributed in the arterial wall) and the long tibial chronic total occlusions. Percutaneous transluminal angioplasty achieves a technically successful result (<30% residual stenosis) in most cases, but it is limited by high restenosis rates. Although several devices have been used in the IP arena (including orbital and directional atherectomy, laser atherectomy, "contact" atherectomy [CROSSER, Bard], and re-entry devices), percutaneous transluminal angioplasty with plain old balloons has been the subject of most studies with several modified iterations, that is, cryoplasty, cutting balloons, focal force balloons, nitinol-"cage"-constrained balloons, tapered balloons, and most recently drug-coated balloons. In this article, we share our current approach to endovascular IP endovascular interventions. We cover the spectrum from pathophysiology, clinical indications, equipment choices, and procedural steps used in our laboratory when treating patients with CLI (which is synonymous with complex anatomy). Regarding what represents the "gold standard" for the treatment of IP disease, a definite answer is currently not available, as multiple studies looking at new generation drug-coated balloons used alone or in combination with different forms of atherectomy are currently under way. We anxiously wait for these results and in the meantime continue to design newer approaches.
胫动脉疾病是对抗严重肢体缺血(CLI)这场战斗中的最后一个前沿领域。孤立性腘下(IP)疾病主要见于老年患者(>80岁)、糖尿病患者以及依赖透析的CLI患者。随着基于导管技术的发展与演进,血管内治疗(主要是球囊血管成形术)已成为这些患者血运重建的首选方法。最常见的挑战是严重钙化病变难以扩张(因为钙在动脉壁中分布不均)以及较长的胫动脉慢性完全闭塞。经皮腔内血管成形术在大多数情况下能取得技术上成功的结果(残余狭窄<30%),但受高再狭窄率限制。尽管在IP领域已使用了多种器械(包括轨道旋切术和定向旋切术、激光旋切术、“接触式”旋切术[CROSSER,巴德公司]以及再通器械),但使用普通球囊的经皮腔内血管成形术一直是大多数研究的主题,有多种改良迭代方式,即冷冻球囊血管成形术、切割球囊、聚焦力球囊、镍钛合金“笼”约束球囊、锥形球囊,以及最近的药物涂层球囊。在本文中,我们分享我们目前对IP血管内介入治疗的方法。我们涵盖了从病理生理学到临床适应证、设备选择以及我们实验室在治疗CLI患者(这与复杂解剖结构同义)时所采用的操作步骤等各个方面。关于什么代表IP疾病治疗的“金标准”,目前尚无明确答案,因为目前正在进行多项研究,观察单独使用新一代药物涂层球囊或与不同形式的旋切术联合使用的情况。我们急切等待这些结果,同时继续设计更新的方法。